Related Experiment Videos
[Dose-intensive chemotherapy with continuous infusion 5-fluorouracil]
T Tichler1, E Ghodsizade, A Katz
1Sheba Medical Center, Tel Hashomer.
Harefuah
|June 23, 2001
Summary
Continuous infusion of 5-fluorouracil (5FU) showed a 37% response rate in advanced cancers. This chemotherapy regimen demonstrated acceptable toxicity, supporting further clinical investigation.
Area of Science:
- Oncology
- Pharmacology
Background:
- Advanced malignancies often become refractory to conventional chemotherapy.
- Exploring novel drug delivery methods and combinations is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy and toxicity of continuous infusion 5-fluorouracil (5FU) in patients with chemotherapy-refractory advanced malignancy.
- To assess the safety profile of this dose-intensive program.
Main Methods:
- A study involving 54 patients with advanced malignancy.
- Administration of continuous infusion 5-fluorouracil (5FU) over 3 weeks, often in combination with other agents.
- Reporting on the first 156 treatment courses.
Main Results:
- A 37% overall response rate (19 out of 54 patients) was observed.
- Complete response was achieved in 6% of patients (3 out of 54).
- Toxicity was deemed acceptable, with mucositis reported in 26% and grade II-III toxicity in 6% of patients.
Conclusions:
- Continuous infusion 5FU demonstrates promising efficacy in advanced, refractory cancers.
- The observed toxicity profile is manageable and supports further investigation.
- This dose-intensive program warrants continued study in disease-oriented clinical trials.